Pfizer Inc. (NYSE:PFE – Get Free Report)’s share price rose 1.3% during trading on Thursday . The stock traded as high as $25.37 and last traded at $25.1330. 44,405,299 shares traded hands during trading, an increase of 4% from the average daily volume of 42,627,141 shares. The stock had previously closed at $24.82.
Pfizer News Summary
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Pfizer received FDA approval for a new PADCEV plus Keytruda regimen in muscle-invasive bladder cancer, expanding the combination’s use as both neoadjuvant and adjuvant therapy and strengthening Pfizer’s oncology growth story. Pfizer (PFE) Wins FDA Approval For First Platinum Free Bladder Cancer Regimen
- Positive Sentiment: Analysts and market commentary continue to point to upside potential, with Pfizer still viewed as inexpensive relative to earnings and offering a high dividend, which may support the stock despite recent weakness. Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now?
- Neutral Sentiment: Several articles framed Pfizer’s shares as fairly priced or in a valuation “middle ground,” suggesting the market is still weighing pipeline progress against longer-term risks rather than assigning a clear premium or discount. Pfizer (PFE) Stock Looks Fairly Priced With Pipeline Risks In View
- Neutral Sentiment: Arbutus Biopharma filed international patent lawsuits against Pfizer and BioNTech over lipid nanoparticle technology used in mRNA vaccines. While this introduces legal overhang, the financial impact remains uncertain at this stage. Reuters: Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges
- Negative Sentiment: Pfizer also said it suspended sales of Premarin vaginal cream in India because of supply challenges, which could be seen as a small setback in an already closely watched portfolio. Reuters: Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges
Wall Street Analyst Weigh In
A number of equities analysts recently weighed in on PFE shares. Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective on the stock in a research report on Tuesday, June 9th. Bank of America cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Guggenheim reduced their target price on shares of Pfizer from $36.00 to $35.00 and set a “buy” rating for the company in a research note on Monday. Citigroup lifted their target price on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a report on Wednesday, April 29th. Finally, BMO Capital Markets dropped their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $28.50.
Pfizer Stock Performance
The stock’s 50 day moving average price is $25.25 and its two-hundred day moving average price is $26.18. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $143.24 billion, a price-to-earnings ratio of 19.19 and a beta of 0.35.
Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts forecast that Pfizer Inc. will post 2.96 EPS for the current year.
Pfizer Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. Pfizer’s dividend payout ratio (DPR) is 131.30%.
Institutional Investors Weigh In On Pfizer
Several institutional investors have recently modified their holdings of the company. Evolution Wealth Management Inc. increased its stake in Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 566 shares in the last quarter. Horizon Financial Services LLC boosted its position in Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 645 shares in the last quarter. Godfrey Financial Associates Inc. acquired a new stake in Pfizer in the fourth quarter valued at $26,000. Keb Asset Management LLC acquired a new stake in Pfizer in the second quarter valued at $26,000. Finally, YANKCOM Partnership purchased a new position in shares of Pfizer in the fourth quarter valued at $28,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.
About Pfizer
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Featured Stories
- Five stocks we like better than Pfizer
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
